Compare ARCO & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARCO | PVLA |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | Uruguay | United States |
| Employees | N/A | 29 |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2011 | N/A |
| Metric | ARCO | PVLA |
|---|---|---|
| Price | $8.21 | $128.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 15 |
| Target Price | $8.60 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 1.2M | 237.1K |
| Earning Date | 05-20-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.56 | N/A |
| Revenue Next Year | $3.48 | $104,350.18 |
| P/E Ratio | $7.26 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.51 | $21.55 |
| 52 Week High | $9.75 | $151.18 |
| Indicator | ARCO | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 41.22 | 61.94 |
| Support Level | $8.03 | $109.68 |
| Resistance Level | $9.07 | $135.23 |
| Average True Range (ATR) | 0.25 | 6.89 |
| MACD | -0.04 | 2.16 |
| Stochastic Oscillator | 15.46 | 96.63 |
Arcos Dorados Holdings Inc operates McDonald's branded restaurants in various countries and territories in Latin America and the Caribbean. The Company manages its business as distinct geographic segments and its operations are divided into three geographic divisions, as follows: Brazil, the North Latin American division, or NOLAD, which is comprised of Costa Rica, Mexico, Panama, Puerto Rico, Martinique, Guadeloupe, French Guiana and the U.S. Virgin Islands of St. Croix and St. Thomas and the South Latin American division, or SLAD, which is comprised of Argentina, Chile, Ecuador, Peru, Uruguay, Colombia, Venezuela, Trinidad and Tobago, Aruba and Curacao. Its menu includes hamburgers, McNuggets, salad, sandwiches, French fries, and others. It generates maximum revenue from Brazil.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.